Literatur
- 1
Santanella R M, Fraunfelder F W.
Ocular adverse effects associated with systemic medications.
Drugs.
2007;
67
75-93
- 2
Baudouin C, Liang H, Hamard P et al.
The ocular surface of glaucoma patients treated over the long term expresses inflammatory
markers related to both T-Helper 1 and T-Helper 2 pathways.
Ophthalmology.
2007;
115
109-115
- 3
Osborne S A, Montgomery D M, Morris D et al.
Alphagan allergy may increase the propensity for multiple eye-drop allergy.
Eye.
2005;
19
129-137
- 4
Yee R W.
The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy:
a review.
Curr Opin Ophthalmol.
2007;
18
134-139
- 5
De Saint Jean M, Brignole F, Bringuier A F et al.
Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells.
Invest Ophthalmol Vis Sci.
1999;
40
619-630
- 6
Jaenen N, Baudouin C, Pouliquen P et al.
Ocular symptoms and signs with preserved and preservative-free glaucoma medications.
Eur J Ophthalmol.
2007;
17
341-349
- 7
Lewis R A, Katz G, Weiss M J et al.
Travoprost 0.004 % with and without benzalkonium chloride: a comparison of safety
and efficacy.
J Glaucoma.
2007;
16
98-103
- 8
Chang D F, Campbell J R.
Intraoperative floppy iris syndrome associated with tamsulosin.
J Cataract Refract Surg.
2005;
31
664-673
- 9
Lui Y, Yanai R, Lu Y et al.
Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal
fibroblasts.
J Glaucoma.
2006;
15
255-259
- 10
Wu K Y, Wang H Z, Hong S J.
Effect of latanoprost on cultured porcine corneal stromal cells.
Curr Eye Res.
2005;
30
871-887
- 11
Sen E, Nalcacioglu P, Yazici A et al.
Comparison of the effects of latanoprost and bimatoprost on central corneal thickness.
J Glaucoma.
2008;
17
398-402
- 12
Hatanaka M, Vessani R M, Elias I R et al.
The effect of prostaglandin analogs and prostamide on central corneal thickness.
J Ocul Pharmacol Ther.
2009;
25
51-53
- 13
Schlote T, Tmamalis A, Kynigopoulos M.
Central corneal thickness (CCT) during treatment with travoprost 0.004 % in glaucoma
patients.
JOPT.
2009;
, in press
- 14
Lass J H, Khosrof S A, Laurence J K et al.
A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide,
timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
Arch Ophthalmol.
1998;
116
1003-1010
- 15
Konowal A, Morrison J C, Brown S V et al.
Irreversible corneal decompensation in patients treated with topical dorzolamide.
Am J Ophthalmol.
1999;
127
403-406
- 16
Gianni L, Panzini I, Li S International Breast Cancer Study Group et al.
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results
from International Breast Cancer Study Group trials.
Cancer.
2006;
106
505-513
- 17
Jonas J B.
Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular
diseases.
Acta Ophthalmol Scand.
2005;
83
645-663
- 18
Alm A, Grierson I, Shields M B.
Side effects associated with prostaglandin analog therapy.
Surv Ophthalmol.
2008;
53 (Suppl. 1)
S93-S105
- 19
Kellner S, Weinitz S, Kellner U.
Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy
similar to multifocal electroretinography, fundus autofluorescence and near-infrared
autofluorescence.
Br J Ophthalmol.
2009;
, [Epub ahead of print]
- 20
Willmore L J, Abelson M B, Ben-Menachem E et al.
Vigabatrin: 2008 update.
Epilepsia.
2009;
50
163-173
- 21
Baath J S, Lam W C, Kirby M et al.
Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
Retina.
2008;
28
894-899
- 22
Wachtlin J, Behme T, Heimann H et al.
Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.
Graefes Arch Clin Exp Ophthalmol.
2003;
241
518-521
- 23
Mauget-Faÿsse M, Gambrelle J, Quaranta-El Maftouhi M.
Optical coherence tomography in tamoxifen retinopathy.
Breast Cancer Res Treat.
2006;
99
117-118
- 24
Bouzas E A, Karadimas P, Pournaras C J.
Central serous chorioretinopathy and glucocorticoids.
Surv Ophthalmol.
2002;
47
431-448
- 25
Fraunfelder F W, Fraunfelder F T.
Central serous chorioretinopathy associated with sildenafil.
Retina.
2008;
28
606-609
- 26
Cardascia N, Boscia F, Furino C et al.
Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy.
Int Ophthalmol.
2008;
28
383-385
- 27
Yuen D, Gonder J, Proulx A et al.
Comparison of the in vitro safety of intraocular dyes using two retinal cell lines:
a focus on brilliant blue G and indocyanine green.
Am J Ophthalmol.
2009;
147
251-259
- 28
Menon V, Jain D, Saxena R et al.
Prospective evaluation of visual function for early detection of ethambutol toxicity.
Br J Ophthalmol.
2009;
93
1251-1254
- 29
Johnson L N, Krohel G B, Thomas E R.
The clinical spectrum of amiodarone-associated optic neuropathy.
J Natl Med Assoc.
2004;
96
1477-1491
- 30
Laties A M.
Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence
to date.
Drug Saf.
2009;
32
1-18
- 31
Stoffelns B M.
Interferon löst okuläre Ischämien aus. Fallserie und Literaturüberblick.
Klin Monatsbl Augenheilkd.
2006;
223
367-371
- 32 Schlote T, Rohrbach J M. Sekundärglaukome: komplizierte Glaukome in Theorie und
Praxis. Stuttgart; Schattauer 2004: 71
- 33 Kellner U.
Chloroquin- und Hydroxychloroquin-Retinopathie. Heimann H, Kellner U Atlas des Augenhintergrundes. Stuttgart; Thieme 2009
1 Beide Autoren haben einen gleichwertigen Beitrag zur Entstehung dieser Publikation
geleistet.
Prof. Dr. med. Torsten Schlote
Tagesklinik Ambimed Basel
Klingentalstraße 9
4057 Basel
Schweiz
Email: praxis.schlote@bluewin.ch
Prof. Dr. med. Ulrich Kellner
RetinaScience
AugenZentrum Siegburg
Europaplatz 3
53721 Siegburg
Email: kellneru@retinascience.de
